Doravirine for children with HIV infection and stable treatment
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This Phase 2 study tests doravirine (a type of HIV medicine) in children with HIV who are about 4 weeks to under 12 years old and weigh under 45 kg. It aims to see whether this regimen can control the virus safely, and some children may continue into an extension if they benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A confirmed HIV-1 infection (the virus type) at the screening visit
- Age is from about 4 weeks old to under 12 years old, and weight is over 3 kg but under 45 kg
- Either you haven’t had HIV treatment yet, or your current HIV treatment has kept the viral load under 50 copies/mL for at least 3 months
- If the participant is female who could get pregnant: use approved birth control or have a negative pregnancy test close to starting
- No serious kidney, liver, or pancreas problems (for example, no kidney disease or evidence of liver disease, pancreatitis)
- No certain infections or conditions like active hepatitis, active tuberculosis, or past/current cancers, and no known resistance to doravirine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether switching to a combination of doravirine and raltegravir can safely maintain control of HIV in adults whose virus is already well suppressed. It may help people who are currently on stable HIV treatment and are not resistant to these specific medicines.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
This study tests how to best dose doravirine for pregnant people with HIV who plan to breastfeed after delivery. The goal is to keep the HIV treatment working safely for both pregnancy and breastfeeding.
This study tests a fast-start HIV treatment using doravirine, tenofovir, and lamivudine for people who were just diagnosed with HIV in the last 30 days and have never taken HIV medications before. The goal is to see if starting treatment right away is safe and effective.
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
Hear when a new Human Immunodeficiency Virus (HIV) Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.